Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Condition:   Multiple Myeloma
Interventions:   Other: Autologous Stem Cell Transplant;   Drug: Immunomodulatory Agent;   Drug: Proteasome Inhibitor
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Adaptive Biotechnologies
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 10, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments